Nanoparticles oligosaccharides

K. Niikura, S. Sekiguchi, T. Nishio, T. Masuda, H. Akita, Y. Matsuo, K. Kogure, H. Harashima, and K. Ijho, Oligosaccharide-mediated nuclear hansport of nanoparticles, ChemBioChem, 9 (2008) 2623-2627. 

Huang, L., Cheng, X., Liu, C. et al. 2009. Preparation, characterization, and antibacterial activity of oleic acid-grafted chitosan oligosaccharide nanoparticles. Frontiers of Biology in China 4(3) 321-327. 

Chae, S. Y, Son, S.,Lee, M., Jang, M. K., and Nab, J. W. 2005. Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efheient gene carrier. Journal of Controlled Release 109 330-344. 

Chae SY, Son S, Lee M, Jang MK, Nah JW. Deoxycholic acid-conjugated chitosan oligosaccharide nanoparticles for efficient gene carrier. J Control Release. 2005 109(l-3) 330-44. 

Ying XY, Cui D, Yu L, Du YZ. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym. 2011 84(4) 1357-64. 

Synthetic oligosaccharides also allow the development of new vaccine platforms. For example, gold nanoparticles containing the 21, the T-helper peptide ovalbumin 323-339, and d glucose for stabilization, induce IgG antibodies against the native CPS. It is noteworthy that the antibodies promote opsonophagocytosys of Spl4 bacteria by human leukocytes. 

---